Article Text

Download PDFPDF
Randomised controlled trial
Odds of favourable 3-month outcome following ischaemic stroke are greatest when treatment with intravenous alteplase is initiated up to 90 min following event, with no benefit seen if alteplase is given after 270 min

Statistics from


  • Competing interests RIL has been supported by Boehringer Ingelheim for attending national stroke and cardiovascular conferences. He is the Co-Principal Investigator of the Third International Stroke Trial (IST-3).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.